https://www.selleckchem.com/pr....oducts/amredobresib.
INTRODUCTION A new combination tablet containing sublingual testosterone and oral buspirone (T+ was developed to benefit a subgroup of women suffering from female sexual interest/arousal disorder, caused by dysfunctionally overactive sexual inhibition. AIM The aim of this study was to compare the effect of food intake on the pharmacokinetics of buspirone, administered as a dual-route, dual-release combination tablet containing 0.5 mg testosterone (T) and 10 mg buspirone (. METHODS 19 healthy women took T+B under fed and fasted